A Randomized Controlled Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly

Brief description of study

1) To evaluate the effect of paltusotine versus placebo on IGF-1(Insulin-like growth factor) response 2) To evaluate the effect of paltusotine versus placebo on IGF-1 level 3) To evaluate the effect of paltusotine versus placebo on GH (growth hormone) response 4) To evaluate the effect of paltusotine versus placebo on acromegaly symptoms 1. Proportion of subjects who maintain biochemical response in IGF-1 (less than or equal to 1.0X the upper limit of normal (ULN) at the End of The Randomized Control Phase 1.Change from baseline in IGF-1, in units of ULN, to EOR 2. Proportion of subjects who achieve IGF-1 less than 1.3X ULN at EOR 3.Proportion of subjects with GH less than 1.0 ng/ml at Week 22 4. Change from baseline in Total Acromegaly Symptoms Diary (ASD) score to EOR

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 08 Feb 2023. Study ID: 852026

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).